New Video Available: How Lymphotoxin Beta Receptor (LTβR) Controls Chronic Pain

Watch the full presentation now in the Media Center

In Episode 16 of the PURPOSE Professional Series, Alexei V. Tumanov, MD, PhD, and Armen N. Akopian, PhD, present compelling preclinical evidence identifying lymphotoxin beta receptor (LTβR) as an early master regulator of the acute to chronic pain transition. By bridging mucosal immunology and sensory neuroscience, the speakers demonstrate how LTβR signaling across dorsal root ganglion neurons, dermal fibroblasts, and macrophages coordinates canonical and noncanonical NF-κB inflammatory cascades. Through functional validation across chemotherapy induced neuropathy, inflammatory injury, postviral, and thermal burn models, the presentation outlines how early, localized LTβR blockade disrupts upstream neuroimmune crosstalk to prevent long term chronification. Viewers will gain key insights into the cellular mechanics of peripheral sensitization, the precise therapeutic window required for intervention, and how resetting tissue microenvironment homeostasis offers a promising alternative to conventional analgesics.

Key Learnings:

• Upstream Neuroimmune Regulation: LTβR acts as an early high level node in peripheral tissue, driving broad NF-κB mediated expression of chemokines (such as CCL2 and CCL7) and complement factors across macrophages, fibroblasts, and sensory neurons.
  
  
• Defined Therapeutic Window: Localized LTβR blockade during early transition stages provides permanent protection against chronic pain development, whereas intervention in established chronic states shows little effect.
  
  
• Microenvironment Homeostasis vs. Analgesia: Primary prevention relies on restoring homeostatic equilibrium within the peripheral injury niche rather than directly blocking neuronal ion channels or suppressing central circuits.